GENESIS-PHARMA
1.3.2024 09:38:30 CET | Business Wire | Press release
GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. In the European Union, cemiplimab is indicated for adults as monotherapy treatment for certain patients with locally advanced or metastatic basal cell carcinoma (BCC), as monotherapy treatment for certain patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), as both monotherapy or in combination with chemotherapy for certain patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and as monotherapy treatment for certain patients with recurrent or metastatic cervical cancer.
The two companies will work to seamlessly complete the transition of all relevant commercialization activities by the second quarter of 2024.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “For more than 20 years our company has been committed to ensure patient access to innovative therapies for serious diseases in several European markets building upon a constantly growing network of partners that includes leading global biopharma companies. It is thus our honor to initiate a new agreement with Regeneron, a pioneering company committed to cutting-edge science, that further enhances our long-term expertise and focus on medicines targeting difficult-to-treat cancers.”
About GENESIS Pharma: GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies.
For more information, please visit www.genesispharmagroup.com or follow GENESIS Pharma on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301136761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Advanced MRI Imaging Reveals Changes in Muscle Composition and Fat Infiltration During Obesity Treatment1.10.2026 08:55:00 CEST | Press release
AMRA Chief Scientific Officer Dr. Jennifer Linge will present at EASD 2026, highlighting how quantitative MRI can reveal changes in muscle that conventional measures does not fully capture. As obesity treatment continues to evolve, understanding what happens to muscle during weight loss is becoming increasingly important. At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD),AMRA Medical Chief Scientific Officer Dr. Jennifer Linge will present how advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930545312/en/ Advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment The presentation addresses an increasingly important question in obesity research: what happens to muscle as people lose weight?Understanding muscle
Ares Strengthens Commitment to Plenitude Through €1 Billion Capital Contribution1.10.2026 08:30:00 CEST | Press release
Reorganization of Plenitude’s capital structure expands Ares’ economic and governance participation in the company Ares Management Corporation (NYSE: ARES), a leading global investment manager, announced today that Ares Alternative Credit funds (“Ares”) participated in a reorganization of the shareholding and governance structure of Plenitude through which Ares and Eni S.p.A (“Eni”) upsized their capital contribution by approximately €1.5 billion, of which over €1 billion is attributable to Ares, based on a pre-money equity valuation of Plenitude of €10.75 billion. Following completion of the transaction, Ares holds 26.24% of Plenitude’s share capital, with Eni holding 65.03% and Energy Infrastructure Partners (“EIP”) as an 8.73% shareholder. Ares first invested in Plenitude in 2025, acquiring a 20% stake in the business for approximately €2 billion. This transaction is geared towards strengthening Plenitude’s capital structure and introduces an enhanced governance framework that suppo
Orifarm Unveils 2031 Strategy to Accelerate Growth Across Europe, With Significant Expansion in Generics1.10.2026 08:10:00 CEST | Press release
With its five-year strategy, Fit to Scale, Orifarm sets out an ambitious path to scale across Europe, including a major expansion of its prescription medicines business from a Nordic footprint to a broader European platform. The strategy aims to double EBITDA to €300m and generate more than €3bn in revenue by 2031, marking the next step in Orifarm's journey as a diversified European pharmaceutical company bringing affordable medicines to more customers, patients and healthcare systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930257993/en/ Orifarm Headquarter, Odense Denmark “As European healthcare systems face rising demand, budget pressures, and supply challenges, Orifarm is uniquely positioned to improve access to affordable medicines and strengthen European supply. Our Fit to Scale strategy is about playing an even bigger role in meeting these needs and taking Orifarm to the next level,” says Mads Fink Eriksen,
Thales Launches Sentinel Envelope Plus to Protect Software Against AI-Assisted Reverse Engineering1.10.2026 08:01:00 CEST | Press release
Sentinel Envelope Plus, a new advanced software protection add-on, helps software vendors protect compiled applications against AI-assisted reverse engineering, automated vulnerability discovery, and exploit generation without requiring source code changes In a controlled test, an AI agent identified eight of 10 vulnerabilities in an unprotected application; once the application was protected with Sentinel Envelope Plus, it found none, and the analysis was halted after nearly seven hours. Thales, a global leader in advanced technologies, today announced Sentinel Envelope Plus, a new addition to its Sentinel Envelope software protection solution that significantly hardens compiled applications against AI-assisted reverse engineering, automated zero-day vulnerability discovery, and automated exploit generation. Sentinel Envelope Plus applies multiple layers of protection to software applications, without requiring source code changes or any special compilation environments. This press re
NHOA Energy Achieves UNI/PdR 125:2022 Gender Equality Certification1.10.2026 08:00:00 CEST | Press release
The certification marks another step in NHOA Energy’s commitment to equal opportunities and inclusive workplace NHOA Energy, global provider of utility-scale energy storage systems, has obtained the UNI/PdR 125:2022 Gender Equality Certification for its Gender Equality Management System in Italy. Issued by RINA following an independent audit, the certification evaluates the Company’s approach to gender equality through qualitative and quantitative indicators across six key areas: recruitment and hiring, career management, pay equity, parenting and caregiving, work-life balance, and the prevention of workplace abuse and harassment. “Building a strong company also means creating an environment where people have equal opportunities to contribute, grow and lead. This certification is an important recognition of the work already done, but above all a commitment to continue improving the way we support our People and strengthen our culture,” said Anita Maria Ganassali, VP Human Capital of NH
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom